Angelman Syndrom

GeneTx Biotherapeutics LLC and Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) have received clearance from Health Canada to begin enrolling in the Phase 1/2 study of GTX-102 pediatric patients with Angelman syndrome in Canada. Angelman syndrome is a rare neurogenetic...

The Cowen Group has initiated coverage on Ovid Therapeutics Inc (NASDAQ: OVID) with an Outperform rating and $14.48 price target. It's Time To Tackle Orphan Neurological Disorders Until now, the biopharmaceutical industry has mostly ignored orphan neurological disorders due to the difficulty of...